Validation of the MiCK Assay

Mayo Clinic Validation of the MiCK Assay

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01770665

Acronym

MiCK Assay

Enrollment

Registered

2013-01-18

Start date

2012-06-30

Completion date

2016-09-30

Last updated

2016-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mesothelioma, Small Cell Lung Cancer, NSCLC

Brief summary

Testing Mayo Clinic cancer patients with the results being correlated with prior patient therapy, performance status, and extent of disease.

Detailed description

This study will be conducted in two phases. During the Feasibility Phase, specimens from any tumor will be sent to the central DiaTech MiCK assay laboratory to determine the ease of sample acquisition, processing, transport, and assay interpretation. Once DiaTech has completed analyses for the feasibility phase specimens and has confirmed that the sample acquisition, processing, transport, and assay interpretation are appropriate, we will proceed with the Demonstration Phase. During the Mesothelioma Demonstration Phase, 20 mesothelioma samples will be assayed and the results will be correlated with prior patient therapy, performance status, and extent of disease.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* 20 subjects diagnosed with mesothelioma and 10 diagnosed with any malignancy.

Exclusion criteria

* patients that a sample cannot obtained for testing.

Design outcomes

Primary

Measure	Time frame
Complete response and survival	1 year

Countries

United States

Outcome results